Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Kezar Life Sciences, Inc. (KZR) CEO to participate in Cardiorenal Corporate Panel at TD Cowen 44th Annual Health Care Conference. Webcast available on company website.
02/28/2024 - 04:01 PM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co -founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024, at 10:30 a.m. ET.
A webcast of the panel discussion will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com . Following the event, an archived webcast will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel treatments for immune-mediated and oncologic disorders. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. Kezar’s oncology product candidate, KZR-261, targeting the Sec61 translocon and protein secretion pathway, is being evaluated in an open-label dose-escalation Phase 1 clinical trial to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com , and follow us on LinkedIn , Facebook , Twitter and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228522659/en/
Investor and Media Contact:
gjain@kezarbio.com
Source: Kezar Life Sciences, Inc.
When will Chris Kirk participate in the Cardiorenal Corporate Panel?
Chris Kirk will participate in the Cardiorenal Corporate Panel on Tuesday, March 5, 2024, at 10:30 a.m. ET.
Where can the webcast of the panel discussion be accessed?
The webcast of the panel discussion will be available on the 'Events & Presentations' section of Kezar Life Sciences' website at www.kezarlifesciences.com.
For how long will the archived webcast be available on the Kezar website?
The archived webcast will be available on the Kezar website for 90 days following the event.
Kezar Life Sciences Inc
NASDAQ:KZR
KZR Rankings
#5461 Ranked by Stock Gains
KZR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
South San Francisco
About KZR
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
